A new study revealed molecular features linked to more aggressive prostate cancer in a subset of patients who had been classified as low risk, highlighting biological differences that may not be apparent from clinical measures alone. The results could lead to new therapeutic strategies.

Researchers have carried out the first single-cell analysis of mitochondrial DNA in a population of brainstem neurons that are particularly vulnerable to degeneration in Parkinson’s disease.

Researchers at Fred Hutch Cancer Center have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more aggressive, drug-resistant form of the disease.